|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2008-3-19
|
|
pubmed:abstractText |
Increased systemic exposure of the antidepressant venlafaxine and increased risk of side effects has previously been observed in patients with defective CYP2D6 function [poor metabolisers (PMs)]. The aim of this study was to evaluate venlafaxine pharmacokinetics in carriers of one functional and one defective CYP2D6 allele [heterozygous extensive metabolisers (HEMs)].
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1432-1041
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
64
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
483-7
|
|
pubmed:meshHeading |
pubmed-meshheading:18214456-Adult,
pubmed-meshheading:18214456-Aged,
pubmed-meshheading:18214456-Aged, 80 and over,
pubmed-meshheading:18214456-Alleles,
pubmed-meshheading:18214456-Antidepressive Agents, Second-Generation,
pubmed-meshheading:18214456-Cyclohexanols,
pubmed-meshheading:18214456-Cytochrome P-450 CYP2D6,
pubmed-meshheading:18214456-Female,
pubmed-meshheading:18214456-Genotype,
pubmed-meshheading:18214456-Heterozygote,
pubmed-meshheading:18214456-Humans,
pubmed-meshheading:18214456-Male,
pubmed-meshheading:18214456-Middle Aged,
pubmed-meshheading:18214456-Retrospective Studies
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D6*3, *4 or *5 allele.
|
|
pubmed:affiliation |
Department of Psychopharmacology, Diakonhjemmet Hospital, P.O. Box 85, Vinderen N-0319, Oslo, Norway. monica.hermann@diakonsyk.no
|
|
pubmed:publicationType |
Journal Article
|
